NewAmsterdam Pharma Company (NAMS) Company Profile

Complete business overview, executive team, trading details, and corporate information.

NewAmsterdam Pharma Company N.V.

NAMS•Nasdaq Stock Market•Healthcare•Biotechnology

About NewAmsterdam Pharma Company

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)

CurrencyUSD - USD

TypeStock

Contact Information

Websitewww.newamsterdampharma.com

Phone31 35 206 2971

Address

Gooimeer 2-35 Naarden, 1411 DC Netherlands

Corporate Identifiers

CIK0001936258

ISINNL00150012L7

SIC2834

Leadership Team & Key Executives

Dr. Michael Harvey Davidson FACC, Facp., M.D.

Chief Executive Officer, President and Executive Director

Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.

Founder, Chief Scientific Officer, Member of Executive Board and Director

Mayur Amrat Somaiya

Chief Financial Officer

Douglas F. Kling

Chief Operating Officer

Louise Kooij

Chief Accounting Officer

Matthew Philippe

Executive Vice President and Head of Investor Relations

Michael F. Marino Esq.

Chief Legal Officer and Corporate Secretary

Chris Deluzio

Executive Vice President of Sales Enterprise Operations

Maryellen McQuade

Chief People Officer

Juliette Audet M.B.A., M.Sc.

Chief Strategy and Business Officer

About NewAmsterdam Pharma Company

Company Information

Stock Details

Contact Information

Corporate Identifiers

Leadership Team & Key Executives